Literature DB >> 9700431

Using a double blind controlled clinical trial to evaluate the function of a Diabetes Advisory System: a feasible approach?

O K Hejlesen1, S Andreassen, N E Frandsen, T B Sørensen, S H Sandø, R Hovorka, D A Cavan.   

Abstract

This paper assesses the feasibility of using a double blind controlled clinical trial to evaluate the function of a decision support system by applying such a design to the evaluation of a Diabetes Advisory System (DIAS). DIAS is based on a model of the human carbohydrate metabolism and is designed an interactive clinical tool, which can be used to predict the effects of changes in insulin dose or food intake on the blood glucose concentration in patients with insulin dependent diabetes. It can also be used to identify risk periods for hypoglycaemia. and to provide advice on insulin dose. The latter feature was evaluated in the present study. We believe double blind controlled clinical trials are prerequisites for clinical application of many decision support systems, and conclude that the present double blind controlled clinical trial is a suitable evaluation method for the function of DIAS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700431     DOI: 10.1016/s0169-2607(98)00023-6

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  3 in total

1.  Hypoglycemia impairs quality of blood glucose simulation in a clinical decision support system.

Authors:  Mette Dencker Johansen; Ole K Hejlesen; David A Cavan
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

2.  Multi-objective blood glucose control for type 1 diabetes.

Authors:  Pinky Dua; Francis J Doyle; Efstratios N Pistikopoulos
Journal:  Med Biol Eng Comput       Date:  2009-02-13       Impact factor: 2.602

3.  A Survey of Insulin-Dependent Diabetes-Part II: Control Methods.

Authors:  Daisuke Takahashi; Yang Xiao; Fei Hu
Journal:  Int J Telemed Appl       Date:  2008
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.